News coverage about Abbott Laboratories (NYSE:ABT) has trended somewhat positive on Tuesday, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Abbott Laboratories earned a daily sentiment score of 0.19 on Accern’s scale. Accern also assigned media coverage about the healthcare product maker an impact score of 46.3223703842271 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the headlines that may have impacted Accern Sentiment’s scoring:
- Spinal-Cord Implants to Numb Pain Emerge as Alternative to Pills (finance.yahoo.com)
- Abbott Laboratories (ABT) Given Average Rating of “Buy” by Brokerages (americanbankingnews.com)
- Diamond Hill Capital Management Has Cut Abbott Laboratories (ABT) Holding; Orbimed Advisors Upped Vertex … – Hill Country Times (hillcountrytimes.com)
- Apple Reverses Higher; Will Bitcoin ETF End Its Losing Streak? (finance.yahoo.com)
- Analysts issued consensus rating score of 2.00 for Abbott Laboratories (ABT) – Wall Street Morning (wallstreetmorning.com)
Several research analysts have recently commented on ABT shares. Zacks Investment Research upgraded shares of Abbott Laboratories from a “hold” rating to a “buy” rating and set a $61.00 price target on the stock in a research note on Tuesday, October 31st. Royal Bank of Canada restated a “buy” rating and set a $55.00 price target on shares of Abbott Laboratories in a research note on Tuesday, October 3rd. Jefferies Group reiterated a “buy” rating and issued a $65.00 target price on shares of Abbott Laboratories in a research note on Thursday, October 19th. Bank of America reiterated a “buy” rating and issued a $60.00 target price (up from $56.00) on shares of Abbott Laboratories in a research note on Wednesday, October 4th. Finally, ValuEngine lowered shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and ten have issued a buy rating to the company’s stock. Abbott Laboratories presently has a consensus rating of “Buy” and an average price target of $57.56.
Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Wednesday, October 18th. The healthcare product maker reported $0.66 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.01. Abbott Laboratories had a net margin of 8.37% and a return on equity of 13.98%. The firm had revenue of $6.83 billion during the quarter, compared to the consensus estimate of $6.72 billion. During the same period in the prior year, the firm earned $0.59 EPS. The business’s revenue was up 28.8% on a year-over-year basis. equities research analysts forecast that Abbott Laboratories will post 2.5 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, February 15th. Shareholders of record on Friday, January 12th will be issued a $0.28 dividend. The ex-dividend date is Thursday, January 11th. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.27. This represents a $1.12 dividend on an annualized basis and a yield of 1.97%. Abbott Laboratories’s dividend payout ratio is 83.47%.
In other news, insider Daniel Gesua Sive Salvadori sold 71,157 shares of the firm’s stock in a transaction dated Tuesday, November 14th. The shares were sold at an average price of $55.00, for a total transaction of $3,913,635.00. Following the completion of the transaction, the insider now directly owns 144,955 shares of the company’s stock, valued at approximately $7,972,525. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Alejandro D. Wellisch sold 2,153 shares of the firm’s stock in a transaction dated Wednesday, November 22nd. The stock was sold at an average price of $55.86, for a total transaction of $120,266.58. Following the transaction, the insider now directly owns 10,256 shares of the company’s stock, valued at $572,900.16. The disclosure for this sale can be found here. Over the last three months, insiders sold 501,172 shares of company stock valued at $27,533,150. Insiders own 0.76% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was first posted by Community Financial News and is the property of of Community Financial News. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this report can be viewed at https://www.com-unik.info/2017/12/26/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-abbott-laboratories-abt-stock-price.html.
Abbott Laboratories Company Profile
Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.